September 26th 2025
The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant costs.
Consent Decree Against Oklahoma Drug Compounder Enters Federal Court
December 21st 2022The complaint states the company introduced adulterated drugs into interstate commerce that were manufactured, processed, packed, or held under conditions that defy current good manufacturing practice (CGMP) requirements.